Skip to content

Spaceflight-Associated Neuro-ocular Syndrome Countermeasures study

Spaceflight-Associated Neuro-ocular Syndrome Countermeasures study - SANS-CM 1 + 2

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00027643
Enrollment
24
Registered
2022-01-12
Start date
2021-09-27
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle atrophy, bone loss, deconditioning of the cardiovascular system, deterioration of the vestibular system, deterioration of cognitive performance, fluid shifts, eye changes, SANS

Interventions

Group 1: 6 subjects will be immobilized in a 6° head-down position for 30 days. They spend 2 x 3 hours per day in a LBNP (Lower Body Negative Pressure). Group 2: 6 subjects are immobilized for 30 days

Sponsors

DLR Deutsches Zentrum für Luft- und RaumfahrtInstitut für Luft- und Raumfahrtmedizin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
24 Years to 55 Years

Inclusion criteria

Inclusion criteria: - Male and female, healthy volunteers, aged 24-55 years, with a body mass index (BMI) of 19-30 kg/m2 and a height of 153-190 cm - Non-smokers, smoking cessation at least six months prior to study entry - Subjects willing and able to participate in the entire study - Present certificate of health insurance and police clearance certificate - Successful completion of the medical and psychological inclusion examination - Present informed consent at the beginning of the study - Presentation of a dental certificate

Exclusion criteria

Exclusion criteria: - Any illness, injury, or medical condition that could prevent safe participation in the study or result in a significant bias in the scientific results - Drug, medication or alcohol abuse (regular consumption of more than 30 g alcohol/day). - Need for any form of prescription medication. Exception: hormonal contraceptives, which do not cause a significant increase in the risk of thrombosis. In this case, hormonal contraception must be used for the entire duration of the study. - Smoker (also e-cigarettes, shisha, e-shisha etc.) - Vegetarianism, veganism during the study period - Claustrophobia (fear of actual or perceived confinement, fear of confined spaces) - Increased intraocular pressure - Eye problems with a significant impact on vision - Laser eye surgery for visual acuity correction - Severe long-sightedness > +5 dpt. - Astigmatism (astigmatism of the cornea) > 3 dpt. - Significant chronic discomfort due to gastroesophageal reflux ("heartburn") - Current or past disc herniation - Chronic back pain - Kidney stones, current or past - Increased risk of thrombosis * - Pronounced orthostatic intolerance (blood pressure regulation disorder occurring when changing to an upright position (orthostasis) ) - Current or past bleeding tendency or coagulation disorders - In female candidates: Existing pregnancy or lactation Menopause or post-menopause - Any medical or orthopedic condition that would interfere with participation in the bed rest or any of the examinations to be performed (e.g., diabetes, severe rheumatism, hypertension requiring treatment, etc.). The decision is up to the study physician. - Bone density of femur and lumbar spine (L1-4) < -2.0 SD t-score. - Metal implants, other osteosynthesis materials, implants, tattoos, or permanent makeup that are not MRI compatible or interfere with examinations due to their location. - Participation in another clinical trial within the last 3 months prior to the start of this study, if the study design conflicts with this study (e.g., certain drug trials) - Chronic tinnitus, severe hearing loss or implanted hearing aid - Allergies to a degree that requires the constant presence of an emergency kit - Any other condition that, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study - Entry in EU and US counterterrorism databases

Design outcomes

Primary

MeasureTime frame
Study Objective: Maintaining astronaut safety and well-being is essential for successful future long-term missions aboard the International Space Station (ISS), on the Moon, and eventually on Mars.

Countries

Germany

Contacts

Public ContactEdwin Mulder

DLR - Institut für Luft- und Raumfahrt

Edwin.Mulder@dlr.de+4922036013362

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026